The real downsides of Mounjaro, according to the trial data

Side effects: what the SURMOUNT trials actually recorded

The most thorough source on Mounjaro's downsides is the SURMOUNT-1 trial, published in the New England Journal of Medicine, which randomised 2,539 adults with obesity across 72 weeks. The side-effect record is clear: gastrointestinal problems were far more common in the tirzepatide groups than in the placebo group. Nausea, diarrhoea, vomiting, constipation and indigestion all appeared at rates that declined as participants settled into each dose level, but they were the main reason people discontinued treatment in the trial.

The NHS medicines page for tirzepatide lists the common side effects in plain language: nausea, vomiting, diarrhoea, constipation, stomach pain, burping, reflux, fatigue, dizziness and injection-site reactions. These are not hypothetical risks. Most people experience at least one of them, typically in the first few days after starting or after a dose increase, with symptoms usually easing within one to two weeks. Severe cases are less common but can lead to dehydration, which carries its own complications.

There is also a smaller-print concern worth knowing. In January 2026, the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines including tirzepatide. The symptom to act on immediately is severe, persistent abdominal pain that radiates to the back, with or without vomiting. Anyone who experiences that should seek urgent medical attention rather than waiting for their next check-in.

For a fuller breakdown of the side-effect profile, the complete Mounjaro side effects guide covers each one in detail.

The titration timeline: why results take longer than adverts suggest

One downside that surprises people is how long the schedule takes. Mounjaro begins at 2.5 mg — a dose chosen primarily to let your digestive system adjust, not to produce weight loss. The prescriber then increases the dose roughly every four weeks, working through 5, 7.5, 10, 12.5 and potentially 15 mg. Reaching the higher therapeutic doses where the trial results were recorded can take the better part of six months.

That means the weight-loss figures from SURMOUNT-1 (around 20–21% average reduction at 15 mg over 72 weeks) reflect a long journey, not a quick fix. People who expect dramatic change in the first month are often disappointed, and that disappointment is itself a reason some discontinue early. If you want to understand why weight loss can seem to stall partway through, the explanation of why progress slows on Mounjaro is worth reading before you start, not after.

It's also worth noting that the trial's best results came from people who maintained reduced-calorie eating and increased activity alongside the medicine. Mounjaro helps reduce appetite significantly, but it does not replace dietary effort. Anyone expecting a purely passive outcome is likely to find the reality disappointing.

Practical and financial demands of long-term treatment

Tirzepatide is a weekly injection that must be kept refrigerated between 2 and 8 °C, sitting it in the fridge door next to everyday items is fine for storage, but it cannot be left at room temperature indefinitely. Travelling requires a cool bag. Forgetting to order on time means a gap in treatment. These are real-world logistics that the trial setting does not capture.

Cost is another honest downside. Eli Lilly raised the UK list price of Mounjaro significantly from September 2025, with the highest-dose pen's list price rising to around £330; typical private prices across providers since then range roughly £149 to £375 per month depending on the dose and clinic. That is a substantial ongoing expense, and it is why understanding what the price covers matters before committing. A single transparent price that includes your prescription, clinical review, delivery and aftercare is very different from a headline figure that excludes those things. For a broader look at what treatment can and cannot achieve, the overview of Mounjaro's effects beyond weight gives the fuller picture.

Mounjaro is not recommended during pregnancy, for anyone breastfeeding, or for those actively trying to conceive; it is not licensed for under-18s. History of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis or certain gastrointestinal conditions requires careful prescriber discussion before starting. These are not rare edge cases, they are genuine stopping points for a meaningful number of people.

Weighing the downsides: what they tell you and what they don't

None of the above means Mounjaro is the wrong treatment for you. What it means is that the decision deserves the same rigour the clinical trials applied. A prescriber who has reviewed your full health history, current medicines (antihistamines and other drugs can complicate things, interactions are worth checking) and weight trajectory will reach a more reliable conclusion than any article can. The downside of Mounjaro, in plain terms, is that it is a powerful prescription medicine with a real side-effect burden, a slow ramp-up and a non-trivial price, all of which are manageable for the right person, under proper clinical supervision.

If you want to explore your options and have your suitability assessed by a GPhC-registered prescriber, you can start a free consultation with our clinical team. Our prescribers review every consultation personally (the same working day) and are straightforward about whether treatment is right for you.